...
首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.
【24h】

Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.

机译:血清细胞纤连蛋白和基质金属蛋白酶9作为筛查生物标志物以预测急性缺血性脑卒中溶栓后实质血肿的多中心验证性研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND AND PURPOSE: Plasma levels of cellular fibronectin (c-Fn) > or 3.6 microg/mL and of matrix metalloproteinase-9 (MMP-9) > or have been associated with parenchymal hematoma (PH) after treatment with tissue-type plasminogen activator (t-PA) in patients with acute ischemic stroke. In this prospective study, we sought to validate the predictive capacity of the preestablished cutoff values of these biomarkers for PH in a larger series of patients. METHODS: We studied 134 patients treated with t-PA within 3 hours from symptom onset according to the SITS-MOST criteria (median time to infusion, 152 minutes; median National Institutes of Health Stroke Scale score, 14) in 4 university hospitals. Hemorrhagic transformation was classified according to the European-Australasian Acute Stroke Study II definitions on computed tomography scans performed 24 to 36 hours after treatment. Relevant hemorrhagic transformation was defined as hemorrhagic infarction type 2 or any PH. Serum c-Fn and MMP-9 levels were determined by an ELISA om blood samples obtained before treatment. RESULTS: Cranial computed tomography showed hemorrhagic transformation in 27 patients (20%), hemorrhagic infarction in 15 (type 2 in 8 patients), and PH in 12 patients (symptomatic in 4). Serum c-Fn and MMP-9 concentrations at baseline were significantly higher in patients with relevant hemorrhagic transformation and PH than in those without (all P<0.001). The sensitivity, specificity, and positive and negative predictive values for PH by c-Fn levels > or =3.6 microg/mL were 100%, 60%, 20%, and 100%, respectively, whereas corresponding values were 92%, 74%, 26%, and 99% for MMP-9 levels > or =140 ng/mL. When both biomarkers were at levels above the cutoff points, specificity increased to 87% and the positive predictive value increased to 41%. CONCLUSIONS: This prospective study confirmed the high sensitivity and negative predictive value, with retained good specificity, of c-Fn and MMP-9 for the prediction of PH in patients treated with t-PA. Development of faster analytic methods will prove the applicability of these biomarkers in routine clinical practice.
机译:背景与目的:用组织型纤溶酶原激活物治疗后,血浆纤连蛋白(c-Fn)>或3.6 microg / mL和基质金属蛋白酶9(MMP-9)的水平或已与实质性血肿(PH)相关(t-PA)在急性缺血性中风患者中。在这项前瞻性研究中,我们试图验证这些生物标记物对PH的预测值在更大范围的患者中的预测能力。方法:我们在4所大学医院中根据SITS-MOST标准(输液中位时间为152分钟;美国国立卫生研究院卒中量表评分中位数为14),研究了在症状发作后3小时内接受t-PA治疗的134例患者。根据治疗后24至36小时进行的计算机断层扫描,根据欧洲-澳大利亚人急性卒中研究II定义对出血性转化进行分类。相关的出血性转化定义为2型出血性梗塞或任何PH。通过治疗前获得的血液样本中的ELISA测定血清c-Fn和MMP-9水平。结果:颅骨计算机断层扫描显示27例(20%)有出血性转化,15例(8例2型)出血性梗死,12例(有症状4例)PH。有相关出血性转化和PH的患者的基线时血清c-Fn和MMP-9浓度显着高于无出血和PH的患者(所有P <0.001)。 c-Fn水平>或= 3.6 microg / mL时,PH的敏感性,特异性以及阳性和阴性的预测值分别为100%,60%,20%和100%,而相应的值分别为92%,74% MMP-9水平>或= 140 ng / mL时,分别为26%和99%。当两种生物标志物的水平都高于临界点时,特异性增加到87%,阳性预测值增加到41%。结论:这项前瞻性研究证实了c-Fn和MMP-9对t-PA治疗的患者的PH预测具有较高的敏感性和阴性预测价值,并具有良好的特异性。更快的分析方法的发展将证明这些生物标志物在常规临床实践中的适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号